Charles W. Newton, Director at Keros Therapeutics, sold KROS on Jun 11, 2026
Data as of Oct 16
- Traded
- Jun 11, 2026
- Disclosed
- Jun 15, 2026
- Filed
- 4 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
KROS since disclosure
+4.1%
after the sale
Similar stocks (XLV) since disclosure
+15.6%
XLV — its sector index fund
Change in closing price from Jun 15, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.